source
- China clamps down on investigator-initiated clinical trials, tightening oversightChina has announced tighter oversight of investigator-initiated trials (ITTs), requiring these studies to obtain approval from the National Medical Products Administration before they can begin. Th…
- RevMed partners with BeOne for Asian rights to RAS drugs as MoonLake reports Phase 3 successRevMed and BeOne have entered a partnership granting BeOne rights to commercialize RevMed’s RAS pathway drugs in selected Asian markets. The agreement also includes collaboration on upcoming clini…